Overview
Magnus Medical developed SAINT (Stanford Accelerated Intelligent Neuromodulation Therapy), a personalized TMS protocol that uses fMRI-guided targeting to deliver rapid antidepressant effects. Their system received FDA Breakthrough Device designation and aims to compress weeks of TMS treatment into days.
More in Brain-Computer Interfaces
Latest industry news
FDA Grants De Novo Approval to Modius Spero, Clearing First Neuromodulation Device for PTSD
2026-09-03 · Policy
Butterfly Network's BCI Chip Licensing Deal Rattles Investors as Shares Drop Nearly 10%
2026-09-02 · Industry
Merge Labs and Butterfly Network Unite to Push Ultrasound-Based BCIs Into the Mainstream
2026-09-01 · Industry
FDA Grants CorTec Second Breakthrough Device Designation for Its Brain-Computer Interface
2026-08-31 · Policy
Company details
Category
🧠 Brain-Computer Interfaces
Location
Burlingame, USA
Funding
Series B · $50M
Website
magnusmedical.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →